epigallocatechin gallate has been researched along with oxidopamine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amit, T; Levites, Y; Mandel, S; Youdim, MB | 1 |
Chan, P; Wang, L; Xu, S; Xu, X | 1 |
Allbutt, HN; Creber, NJ; Henderson, JM; Kassiou, M; Leaver, KR | 1 |
Chan, TH; Chang, RC; Chao, J; Ho, YS; Huie, MJ; Lai, CS; Lam, WH; Lau, WK; Wang, M; Yu, MS; Yuen, WH | 1 |
4 other study(ies) available for epigallocatechin gallate and oxidopamine
Article | Year |
---|---|
Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action.
Topics: bcl-2-Associated X Protein; Catechin; Cell Cycle; Cell Survival; Cells, Cultured; Enzyme Activation; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Oxidopamine; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tea | 2002 |
(-)-Epigallocatechin-3-Gallate protects SH-SY5Y cells against 6-OHDA-induced cell death through STAT3 activation.
Topics: Adrenergic Agents; Analysis of Variance; Catechin; Cell Death; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Humans; Neuroblastoma; Neuroprotective Agents; Oxidopamine; STAT3 Transcription Factor; Tetrazolium Salts; Thiazoles; Thymidine; Time Factors; Tritium; Tyrosine | 2009 |
Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antioxidants; Catechin; Cell Count; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Motor Activity; Neurons; Neuropsychological Tests; Oxidopamine; Posture; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra | 2009 |
A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine.
Topics: Caspase 3; Catechin; Cell Line, Tumor; Central Nervous System Agents; Dose-Response Relationship, Drug; Humans; L-Lactate Dehydrogenase; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; Tretinoin | 2010 |